Fatty Acid Amide Hydrolase
FAAH breaks down anandamide and other endocannabinoids — the body's own cannabinoid signals. A common variant (Pro129Thr, rs324420) reduces enzyme activity, leaving endocannabinoid tone slightly elevated. Studies have linked it to differences in pain perception, anxiety, and how people respond to cannabis and to FAAH-inhibitor drugs in development.
Gene2Rx reports your FAAH genotype across 2 named alleles, built from 1 variant curated by PharmVar.
FAAH alleles are named by the underlying DNA variant rather than a star number — for example c.61C>T describes a single base change at position 61 of the coding sequence.
You inherit one allele from each parent, and the pair determines whether your FAAH activity is normal, decreased, or absent.
PharmVar is the international registry that curates these names. Gene2Rx tests every variant needed to call each cataloged FAAH allele.
Gene2Rx covers 1 medication with published pharmacogenetic guidance for FAAH, drawn from CPIC and FDA sources. Each drug links to its full pharmacogenetics page.
This page lists drugs affected by FAAH. A Gene2Rx report tells you which metabolizer group you fall into, and what that means for every medication on this list.
Get your report Look up a medicationInformational only, not medical advice. The presence of a FAAH pharmacogenetic guideline does not mean every patient needs to change their dose. Never start, stop, or change a medication without talking to your prescribing clinician.